| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5655577 | Digestive and Liver Disease | 2017 | 41 Pages |
Abstract
L-HSA-DOXO shows at least comparable activity to sorafenib which clinically achieves only â¼3 months overall survival benefit. Combination of these two agents could act beneficially or synergistically via two different modes of action to fight HCC.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Bakheet Elsadek, Ahmed Mansour, Tahia Saleem, André Warnecke, Felix Kratz,